The correct way to take Vibutuximab

Welbutuximab, a CD30-directed antibody-drug conjugate (ADC), has shown significant efficacy in the treatment of Hodgkin lymphoma, anaplastic large cell lymphoma, peripheral T-cell lymphoma, mycosis fungoides, and large B-cell lymphoma. However, its correct administration is critical to ensuring the drug's safety and effectiveness.

Welbutuximab is not administered by the oral route but is given as an intravenous infusion. This means that patients cannot take it at home, but must be injected by professional medical staff in a medical institution such as a hospital or clinic. Before the injection, medical staff will make necessary preparations, including checking the dosage of the drug and checking the patient's physical condition, to ensure the safety of the injection process.

For adults with Hodgkin lymphoma, the usual dose of ibtuximab varies depending on the condition. For patients with previously untreated stage III or IV classical Hodgkin lymphoma, the recommended dose is 1.2 mg/kg (maximum 120 mg) administered intravenously over 30 minutes in combination with chemotherapy every 2 weeks until up to 12 doses or until disease progression or unacceptable toxicity. For consolidation therapy in classical Hodgkin lymphoma, as well as in relapsed primary cutaneous anaplastic large cell lymphoma or DC30-expressing mycosis fungoides (MF), the recommended dose is adjusted to 1.8 mg/kg (maximum 180 mg) every 3 weeks until up to 16 cycles, disease progression, or unacceptable toxicity.

For relapsed classical Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma, the recommended dose is also 1.8 mg/kg (maximum 180 mg) every 3 weeks until disease progression or unacceptable toxicity. For pediatric patients with previously untreated high-risk classical Hodgkin lymphoma, the recommended dose of ibtuximab is 1.8 mg/kg administered intravenously over 30 minutes (maximum 180 mg) every 3 weeks for a maximum of 5 doses.

In addition, for adult patients with relapsed or refractory large B-cell lymphoma (LBCL), velbutuximab may be used in combination with lenalidomide and rituximab products at a recommended dose of 1.2 mg/kg, up to a maximum of 120 mg every 3 weeks. Special attention should be paid to the fact that patients with severe renal impairment are prohibited from using this product. If the patient only has mild liver function impairment, the dosage should be reduced as appropriate; while patients with moderate or severe liver function impairment are prohibited from using it.

In short, the correct way to take Vibutuximab must strictly follow the doctor's instructions and be administered intravenously by professional medical personnel. Patients are not allowed to adjust the dosage or administration method by themselves to avoid adverse reactions or affecting the therapeutic effect. At the same time, during the treatment process, patients should pay close attention to their physical condition and promptly inform medical staff if they feel uncomfortable.

Reference materials:https://www.drugs.com/pro/adcetris.html#ID_4f3d2ec8-17ce-4a5b-8d42-0e1baf6cf2a8